Tag Archives: Anti-diversion measures


Breaking News: IPO Official forced out for rejecting Sovaldi patent application? 

Gilead Sciences has been engulfed with controversy ever since it filed for a patent in India for its notoriously expensive blockbuster drug Sofosbuvir (Sovaldi) for Hepatitis C. Now, in a shocking development, Mandakini Gahlot and Vidya Krishnan have reported in their piece for The Caravan that patent-examiner Hardev Karar may have been compelled to withdraw from the Sovaldi case after he rejected Gilead’s patent application in January 2015. Background While the Sovaldi application was initially rejected by the Indian Patent…

Read More »